Sarcoma of Pelvis Clinical Trial
Official title:
Isolated Pelvic and Limb Perfusion With 1mg TNFa in the Treatment of Locally Advanced Sarcoma of Pelvis and Limbs’ Girdle
This study looks at isolated pelvic perfusion and limbs' girdle with 1 mg tumor necrosis factor alpha (TNFa) in the treatment of locally advanced sarcoma of the pelvis and limbs’ girdle.
| Status | Recruiting |
| Enrollment | 33 |
| Est. completion date | |
| Est. primary completion date | |
| Accepts healthy volunteers | No |
| Gender | Both |
| Age group | 16 Years and older |
| Eligibility |
Inclusion Criteria: - Soft tissue or bone sarcomas locally advanced of the pelvis or limbs’ girdle Exclusion Criteria: - Resectable tumor without mutilation |
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Country | Name | City | State |
|---|---|---|---|
| France | Institut Gustave-Roussy | Villejuif |
| Lead Sponsor | Collaborator |
|---|---|
| Gustave Roussy, Cancer Campus, Grand Paris |
France,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Complete response rate on MRI | |||
| Secondary | Histological response | |||
| Secondary | Objective responses | |||
| Secondary | Rate of conservative treatments | |||
| Secondary | Overall survival and disease free survival | |||
| Secondary | Local and systemic toxicity |